GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NewAmsterdam Pharma Co NV (FRA:KH6) » Definitions » Current Deferred Revenue

NewAmsterdam Pharma Co NV (FRA:KH6) Current Deferred Revenue : €8.20 Mil (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is NewAmsterdam Pharma Co NV Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

NewAmsterdam Pharma Co NV's current deferred revenue for the quarter that ended in Dec. 2023 was €8.20 Mil.

NewAmsterdam Pharma Co NV Current Deferred Revenue Historical Data

The historical data trend for NewAmsterdam Pharma Co NV's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NewAmsterdam Pharma Co NV Current Deferred Revenue Chart

NewAmsterdam Pharma Co NV Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Current Deferred Revenue
- - 13.10 8.20

NewAmsterdam Pharma Co NV Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Current Deferred Revenue Get a 7-Day Free Trial - 13.89 13.10 9.72 8.20

NewAmsterdam Pharma Co NV Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of NewAmsterdam Pharma Co NV's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


NewAmsterdam Pharma Co NV (FRA:KH6) Business Description

Traded in Other Exchanges
Address
Gooimeer 2-35, Naarden, NH, NLD, 1411 DC
NewAmsterdam Pharma Co NV is a clinical-stage company focused on the research and development of transformative therapies for metabolic diseases and Alzheimer's disease.

NewAmsterdam Pharma Co NV (FRA:KH6) Headlines

No Headlines